FindTrial
Sign In

Dexmedetomidine versus butorphanol to prevent involuntary muscle contraction caused by etomidate

Comparison of dexmedetomidine with butorphanol for prevention of etomidate induced myoclonus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030855
Enrollment
60
Registered
2021-01-29
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: General Anaesthesia: Test drug will be given. GA will be induced with etomidate. Effect on the myoclonus will be observed. Control Intervention1: 0.015mg/kg Butorphanol diluted in 20ml

Sponsors

University College of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA I/II patients Either gender Age between 18 and 60 years Undergoing elective surgical procedures under general anesthesia

Exclusion criteria

Exclusion criteria: History suggestive of uncontrolled hypertension, epilepsy, bradycardia, heart blocks, heart failure, psychiatric disease, sepsis or systemic infection, neurological disease, asthma, chronic cough History of upper respiratory infection during the 2 weeks before surgery Allergy to dexmedetomidine/butorphanol Those having received any analgesic or sedative within previous 24 hours Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
Incidence of myoclonic movementsTimepoint: After induction of GA—

Secondary

MeasureTime frame
Severity of myoclonusTimepoint: After etomidate injection—

Countries

India

Contacts

Public ContactDr Pramod Kumar

University College of Medical Sciences, Delhi

rsramb@gmail.com9625900699

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026